The project, “ERANET-PLL – Implementation of (epi)genetic and metabolic networks in the targeting of T-cell prolymphocytic leukemia“, was granted funding within the European ERA-net TRANSCAN 2 initiative (Horizon 2020).
The project is a cooperation of five European research groups from Austria, France and Germany, coordinated by Dr. Marco Herling (University Hospital of Cologne). It focuses on the development of new tools to predict individual in vitro drug sensitivities and synergies in the rare entity of T-cell prolymphocytic leukemia and implementation of these into the clinics.
Overall, the project is funded with 1.5 million euros.
For more details visit: